MX2019003598A - Formulaciones orales de derivados de pirrolidina. - Google Patents

Formulaciones orales de derivados de pirrolidina.

Info

Publication number
MX2019003598A
MX2019003598A MX2019003598A MX2019003598A MX2019003598A MX 2019003598 A MX2019003598 A MX 2019003598A MX 2019003598 A MX2019003598 A MX 2019003598A MX 2019003598 A MX2019003598 A MX 2019003598A MX 2019003598 A MX2019003598 A MX 2019003598A
Authority
MX
Mexico
Prior art keywords
oral formulations
pyrrolidine derivatives
present
formulations
methyloxime
Prior art date
Application number
MX2019003598A
Other languages
English (en)
Inventor
Chollet Andre
Pohl Oliver
Original Assignee
ObsEva SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ObsEva SA filed Critical ObsEva SA
Publication of MX2019003598A publication Critical patent/MX2019003598A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)

Abstract

La presente invención se refiere a formulaciones orales sólidas que comprenden un compuesto de la fórmula O-metiloxima de (3Z,5S)-5-(hidroximetil)-1-[(2'-metil-1,1'-bifenil-4-il)carbonil] pirrolidin-3-ona, y/o un metabolito activo del mismo, y al uso de dichas formulaciones en el tratamiento y/o prevención de parto prematuro, nacimiento prematuro, dismenorrea y fracaso de implantación del embrión debido a contracciones uterinas. La presente invención se refiere además a procedimientos para su preparación.
MX2019003598A 2013-12-17 2016-06-16 Formulaciones orales de derivados de pirrolidina. MX2019003598A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13197606.0A EP2886107A1 (en) 2013-12-17 2013-12-17 Oral formulations of pyrrolydine derivatives

Publications (1)

Publication Number Publication Date
MX2019003598A true MX2019003598A (es) 2019-07-15

Family

ID=49765403

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016007930A MX363697B (es) 2013-12-17 2014-12-15 Formulaciones orales de derivados de pirrolidina.
MX2019003598A MX2019003598A (es) 2013-12-17 2016-06-16 Formulaciones orales de derivados de pirrolidina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016007930A MX363697B (es) 2013-12-17 2014-12-15 Formulaciones orales de derivados de pirrolidina.

Country Status (19)

Country Link
US (5) US20170065556A1 (es)
EP (4) EP2886107A1 (es)
JP (2) JP6479800B2 (es)
KR (1) KR102350156B1 (es)
CN (2) CN106029057B (es)
AU (1) AU2014364962B2 (es)
CA (1) CA2931592C (es)
CY (1) CY1119728T1 (es)
DK (1) DK3082773T3 (es)
EA (2) EA031530B1 (es)
ES (2) ES2654927T3 (es)
HK (1) HK1249050B (es)
HU (1) HUE035212T2 (es)
IL (2) IL245855B (es)
MX (2) MX363697B (es)
PT (1) PT3082773T (es)
SI (1) SI3082773T1 (es)
UA (1) UA116824C2 (es)
WO (1) WO2015091365A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
JP2017519015A (ja) * 2014-07-02 2017-07-13 オブセヴァ エス．エー． Ｏｔ−ｒ活性に関する疾患を治療するための方法に有用な結晶質の（３ｚ，５ｓ）−５−（ヒドロキシメチル）−１−［（２’−メチル−１，１’−ビフェニル−４−イル）カルボニル］ピロリジン−３−オン о−メチルオキシム
TWI790189B (zh) 2015-01-02 2023-01-21 美商梅拉洛伊卡公司 細菌組成物
MA43549A (fr) 2016-01-04 2021-05-26 ObsEva SA Alpha-amino esters de dérivé d'hydroxypropylthiazolidine carboxamide, sel et forme cristalline polymorphe correspondants
MA52548A (fr) * 2016-07-21 2021-05-26 ObsEva SA Régimes posologiques d'antagonistes de l'ocytocine pour favoriser l'implantation d'embryons et prévenir les fausses couches
IT201600101413A1 (it) 2016-10-10 2018-04-10 Sofar Swiss S A Composizione liquida per uso nel trattamento del reflusso gastroesofageo
IT201700124434A1 (it) * 2017-10-31 2019-05-01 Sofar Swiss Sa Compressa da succhiare e/o sciogliere in bocca a base di acido ialuronico e condroitina solfato e loro sali per uso nel trattamento di una sottopopolazione di pazienti GERD.
AU2020340670A1 (en) * 2019-09-03 2022-04-07 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CN115380122A (zh) 2020-02-10 2022-11-22 奥布赛瓦股份公司 用于催产素受体拮抗剂疗法的生物标志物
LT3962455T (lt) 2020-05-18 2022-10-25 Orexo Ab Nauja farmacinė kompozicija, skirta vaistų tiekimui
MX2024006188A (es) 2021-11-25 2024-06-11 Orexo Ab Nueva composicion farmaceutica que comprende adrenalina.

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3482815A (en) 1967-07-07 1969-12-09 Victor Naturale Collapsible core for a mold
YU120988A (en) * 1988-06-23 1990-06-30 Lek Tovarna Farmacevtskih Process for preparing new dispersion pills of cimetidine
US4832307A (en) 1988-09-15 1989-05-23 Toshiba Kikai Kabushiki Kaisha Injection mold
YU183988A (en) * 1988-09-30 1990-08-31 Lek Tovarna Farmacevtskih Process for preparing dispersion pills of dihydroergotoxine
JP2927532B2 (ja) 1989-11-09 1999-07-28 塩野義製薬株式会社 含窒素異項環オキシーフェノキシ酢酸誘導体およびその除草剤としての用途
US5889001A (en) 1993-07-29 1999-03-30 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
JP2869854B2 (ja) 1994-10-19 1999-03-10 株式会社トスカ 合成樹脂の成形方法とその装置
JP3534903B2 (ja) 1995-06-09 2004-06-07 鐘淵化学工業株式会社 １−［３−クロロ−（２ｓ）−メチルプロピオニル］−ピロリジン−（２ｓ）−カルボン酸の製造方法
GB9603699D0 (en) * 1996-02-21 1996-04-17 Boots Co Plc Therapeutic composition
US6696484B2 (en) * 1997-10-31 2004-02-24 University Of Chicago Office Of Technology And Intellectual Property Method and compositions for regulation of 5-alpha reductase activity
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP4040878B2 (ja) * 1999-12-09 2008-01-30 レキット ベンキーザー ヘルスケア （ユーケイ） リミテッド 治療薬
ES2261404T3 (es) * 2000-03-27 2006-11-16 Applied Research Systems Ars Holding N.V. Derivados de pirrolidina utiles como inhibidores de bax.
SI1268418T1 (sl) 2000-03-27 2006-10-31 Applied Research Systems Farmacevtsko aktivni pirolidinski derivati kot bax-inhibitorji
JP4350948B2 (ja) 2001-03-20 2009-10-28 ラボラトワール セローノ ソシエテ アノニム オキシトシン調節活性を有するピロリジンエステル誘導体
EA006212B1 (ru) 2001-06-18 2005-10-27 Апплайд Резеч Системз Арс Холдинг Н.В. Оксадиазольные и тиадиазольные производные пирролидина
JP2003192582A (ja) * 2001-12-12 2003-07-09 Merck Patent Gmbh ナプロキセンナトリウムを含む速放性錠剤
UA78058C2 (en) 2002-07-05 2007-02-15 Applied Research Systems Pyrrolidine derivative as oxitocin antagonists
US7557136B2 (en) 2003-02-27 2009-07-07 Laboratoires Serono Sa Pyrrolidine derivatives as oxytocin antagonists
BRPI0508059A (pt) 2004-02-26 2007-07-17 Applied Research Systems método para preparação de pirrolidina oximas
GB2411355B (en) * 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
CA2605923C (en) * 2005-05-10 2012-07-24 Ferring International Center Sa. Use of antagonists of oxytocin and/or vasopressin
WO2007052289A2 (en) * 2005-07-22 2007-05-10 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
EP1978939A2 (en) * 2005-12-27 2008-10-15 Jubilant Organosys Limited Mouth dissolving pharmaceutical composition and process for preparing the same using a high amount of silicon dioxine
JP2008189732A (ja) 2007-02-01 2008-08-21 Fujifilm Corp セルロースアシレート組成物、セルロースアシレートフィルム、光学補償シート、偏光板および液晶表示装置
US20090152770A1 (en) 2007-08-07 2009-06-18 Canon Virginia Inc. Mechanically collapsible core for injection molding
KR101626873B1 (ko) * 2007-10-01 2016-06-02 라보라토리오스 레스비, 에스.엘. 구강붕해정제
US9201077B2 (en) 2009-07-27 2015-12-01 Colorado State University Research Foundation Direct enzyme immunoassay for measurement of serum progesterone levels
JP5942815B2 (ja) 2012-11-26 2016-06-29 株式会社ジェイテクト 等速ジョイント用ブーツの成形金型
JP2016503324A (ja) 2012-11-26 2016-02-04 フェリング ベスローテン フェンノートシャップ 画像解析を使用して子宮収縮レベルを診断するための方法およびシステム
EP2845850A1 (en) 2013-09-10 2015-03-11 ObsEva S.A. Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonists
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
JP2017519015A (ja) 2014-07-02 2017-07-13 オブセヴァ エス．エー． Ｏｔ−ｒ活性に関する疾患を治療するための方法に有用な結晶質の（３ｚ，５ｓ）−５−（ヒドロキシメチル）−１−［（２’−メチル−１，１’−ビフェニル−４−イル）カルボニル］ピロリジン−３−オン о−メチルオキシム
ES2716862T3 (es) 2014-12-22 2019-06-17 Ferring Bv Terapia con antagonistas del receptor de oxitocina en la fase lútea para la implantación y embarazo en mujeres que se someten a tecnologías de reproducción asistida

Also Published As

Publication number Publication date
CN106029057A (zh) 2016-10-12
PT3082773T (pt) 2018-01-09
AU2014364962B2 (en) 2020-03-26
US20150164859A1 (en) 2015-06-18
UA116824C2 (uk) 2018-05-10
CA2931592C (en) 2021-12-07
IL245855A0 (en) 2016-07-31
SI3082773T1 (en) 2018-02-28
EA201892033A3 (ru) 2019-03-29
ES2654927T3 (es) 2018-02-15
WO2015091365A1 (en) 2015-06-25
EP3266449A1 (en) 2018-01-10
US9962367B2 (en) 2018-05-08
HUE035212T2 (en) 2018-05-02
AU2014364962A1 (en) 2016-07-28
US11419851B2 (en) 2022-08-23
IL245855B (en) 2019-02-28
JP2016540758A (ja) 2016-12-28
CN106029057B (zh) 2019-09-03
EP3082773A1 (en) 2016-10-26
EP3266449B1 (en) 2019-02-27
CY1119728T1 (el) 2018-06-27
EP2886107A1 (en) 2015-06-24
JP6479800B2 (ja) 2019-03-06
CA2931592A1 (en) 2015-06-25
US20170065556A1 (en) 2017-03-09
JP2019108336A (ja) 2019-07-04
US20180311211A1 (en) 2018-11-01
CN110960495B (zh) 2022-05-10
CN110960495A (zh) 2020-04-07
HK1249050B (zh) 2020-01-17
EP3494967A1 (en) 2019-06-12
KR102350156B1 (ko) 2022-01-11
EA031530B1 (ru) 2019-01-31
DK3082773T3 (en) 2018-01-08
US20200281892A1 (en) 2020-09-10
US20230226021A1 (en) 2023-07-20
KR20160097359A (ko) 2016-08-17
EA201892033A2 (ru) 2019-02-28
IL264259A (en) 2019-02-28
EP3082773B1 (en) 2017-10-04
MX363697B (es) 2019-03-29
MX2016007930A (es) 2016-09-19
ES2726730T3 (es) 2019-10-08
EA201691061A1 (ru) 2016-11-30
US10478420B2 (en) 2019-11-19

Similar Documents

Publication Publication Date Title
MX2019003598A (es) Formulaciones orales de derivados de pirrolidina.
PH12019500395A1 (en) Amino-pyrrolopyrimidinone compounds and methods of use thereof
MX2018004186A (es) Moduladores del receptor x farnesoide.
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201692280A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX2017006833A (es) Análogos de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
MX367618B (es) Compuestos de benzofuranilo y benzoxazolilo sustituídos, y sus usos.
AR099134A1 (es) Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina
CR20120040A (es) Derivados de 17-hidroxi-17-pentafluoroetil-estra-4,9(10)-dien-11-arilo, procedimientos para su preparación y su uso para el tratamiento de enfermedades
ATE530524T1 (de) Substituierte sulfonamid-derivate
EP4223298A3 (en) Compositions for use in treating heavy menstrual bleeding
EA201500851A1 (ru) ЭСТРА-1,3,5(10),16-ТЕТРАЕН-3-КАРБОКСАМИДЫ ДЛЯ ИНГИБИРОВАНИЯ 17β-ГИДРОКСИСТЕРОИД-ДЕГИДРОГЕНАЗЫ (AKR1C3)
MX2016016751A (es) (3z,5s)-5-(hidroximetil)-1-[(2'-metil-1,1'-bifenil-4-il)carbonil] pirrolidin-3-ona o-metiloxima cristañina y métodos de uso de la misma.
PH12015500823A1 (en) Modified release formulations for oprozomib
UA117154C2 (uk) Антагоністи s1p3
PH12017500089B1 (en) Aldosterone synthase inhibitors
TR201819662T4 (tr) Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi.
PH12018501876A1 (en) Crystalline(2s,4r)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
EA201890616A1 (ru) Сульфонамидные соединения в качестве модуляторов потенциалуправляемых натриевых каналов
AR095834A1 (es) Forma de dosificación de un antagonista del receptor de progesterona, composición farmacéutica
PH12015502703A1 (en) Pharmaceutical compositions
MX354999B (es) Composicion con un inhibidor de la bomba de protones y un antagonista h2.
PH12015502305A1 (en) Use of pidotimod to treat inflammatory bowel disease
BR112014013400A8 (pt) derivados de hidantoína úteis como inibidores de kv3 e uso destes
TR201200570A2 (tr) Anyonik polisakkarit ve antiasit içeren farmasötik terkipler.